Cytokines fluctuation and efficacy of magnesium isoglycyrrhizinate in patients with HBV-related acute-on-chronic liver failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-15007248

Enrollment

Unknown

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related acute-on-chronic liver failure

Interventions

A:Magnesium isoglycyrrhizinate

B:none

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years; 2. Diagnosed with HBV-related acute-on-chronic liver failure.

Exclusion criteria

Exclusion criteria: 1. Other viruses infection, including HCV, HIV; 2. Systematic disorders related to lung, heart, kidney and blood system; 3. Autoimmune liver diseases; 4. Alcoholic liver diseases; 5.Drug-induced liver diseases.

Design outcomes

Primary

Measure	Time frame
Cytokines levels;Mortality rate;	—

Secondary

Measure	Time frame
Total bilirubin level;	—

Countries

China

Contacts

Public ContactZu-Jiang Yu

johnyuem@zzu.edu.cn+86 18603710022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026